LAKESHORE BIOPHARMA CO LTD(LSBCF.US)

Company Encyclopedia

LAKESHORE BIOPHARMA CO LTD

LSBCF.US

1.880 T

LSBCF.USMarket value -Rank by Market Cap -/-

Financial Score

20/01/2026 Update

BiotechnologyIndustry

Industry Ranking153/398

Industry medianC

Industry averageD

Score Analysis

Peer Comparison

Criteria
Rating
Profit ScoreD
- ROE-18.43%E
- Profit Margin-16.26%D
- Gross Margin82.47%A
Growth ScoreC
- Revenue YoY7.41%B
- Net Profit YoY76.90%A
- Total Assets YoY-10.15%E
- Net Assets YoY-15.11%E
Cash ScoreD
- Cash Flow Margin-615.07%E
- OCF YoY7.41%B
Operating ScoreC
- Turnover0.43C
Debt ScoreD
- Gearing Ratio63.46%D

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
Huaqin Xue	51.01%	No Change	04/11/2025
Fung Ching Wong	23.87%	No Change	11/07/2025
Yi Zhang	11.91%	No Change	30/06/2025
Oceanpine Capital Limited	1.12%	No Change	04/11/2025
Hui Shao	0.76%	No Change	30/06/2025
Adjuvant Capital, LP	0.7%	No Change	04/11/2025
Magic Stone Alternative Investments	0.27%	No Change	04/11/2025
Epiphron Capital (Hong Kong) Limited	0.17%	No Change	04/11/2025
Superstring Capital Management LP	0.07%	No Change	04/11/2025
Barclays PLC	0.06%	No Change	30/09/2025

News

Lakeshore Biopharma Faces Imminent Nasdaq Delisting; Company Evaluates Options Ahead of Appeal Deadline

LakeShore Biopharma Co., Ltd (Nasdaq: LSB) faces imminent delisting from Nasdaq due to its stock price falling below the required minimum bid price of $1.00 for 30 consecutive business days. Trading will be suspended on September 22, 2025, unless the company appeals by September 18, 2025. The company is currently evaluating options, including a potential appeal hearing.

Reuters·09/12/2025 21:05

Reuters·09/12/2025 21:05

LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq

LakeShore Biopharma Co Ltd :LAKESHORE BIOPHARMA ANNOUNCES RECEIPT OF DELISTING DETERMINATION LETTER FROM NASDAQ

Reuters·09/12/2025 20:10

Reuters·09/12/2025 20:10

Lakeshore Biopharma Executes 10-for-1 Reverse Stock Split

Lakeshore Biopharma Co., Ltd executed a 10-for-1 reverse stock split on October 1, 2024, consolidating every 10 shares into one. This action was taken to comply with Nasdaq listing requirements. The announcement was published via PR Newswire on September 12, 2025.

Reuters·09/12/2025 20:01

Reuters·09/12/2025 20:01

Lakeshore Biopharma Retains Advisors for Special Committee's Review of Proposal

Lakeshore Biopharma Co., Ltd has appointed Kroll, LLC as its financial advisor and retained Gibson, Dunn & Crutcher LLP and Maples and Calder (Hong Kong) LLP as legal counsel for its independent special committee. This is in relation to the review of a revised preliminary non-binding proposal received on August 26, 2025. The company states that no decisions have been made regarding the proposal, and there is no guarantee of any definitive agreement or transaction.

Reuters·09/10/2025 20:10

Reuters·09/10/2025 20:10

LakeShore Biopharma Receives Revised Proposal for Acquisition and Forms Special Committee for Evaluation

LakeShore Biopharma Co., Ltd. has received a revised non-binding acquisition proposal from a consortium led by Oceanpine Capital and Crystal Peak Investment Inc. The offer remains at US$0.86 per share, with the consortium holding 52.1% of shares agreeing to support the proposal. A special committee of independent directors has been formed to evaluate the proposal, but no decisions have been made yet.

Reuters·08/28/2025 20:04

Reuters·08/28/2025 20:04